%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 14 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R /F4 11 0 R >> /ExtGState << /GS1 12 0 R /GS2 13 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260624062248+00'00') /ModDate (D:20260624062248+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 7 0 R >> endobj 7 0 obj << /Length 6240 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces a Presentation at the 2023)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(ASH Annual Meeting and Advisory Board Meeting)] TJ ET BT 35.000 734.017 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 692.827 Td /F1 12.0 Tf [(TORONTO and SAN MATEO, Calif., Dec. 15, 2023 \(GLOBE NEWSWIRE\) ?? Treadwell)] TJ ET BT 35.000 678.175 Td /F1 12.0 Tf [(Therapeutics, a clinical-stage biotechnology company developing novel first-in-class medicines for)] TJ ET BT 35.000 663.523 Td /F1 12.0 Tf [(unmet needs in cancer, today announced a presentation for the Company??s lead program, CFI-)] TJ ET BT 35.000 648.871 Td /F1 12.0 Tf [(400945, a first-in-class inhibitor of Polo-like Kinase 4 \(PLK4\)being advanced in relapsed/refractory)] TJ ET BT 35.000 634.219 Td /F1 12.0 Tf [(AML, at the 65thAmerican Society of Hematology\(ASH\) Annual Meeting and Exposition being held)] TJ ET BT 35.000 619.567 Td /F1 12.0 Tf [(fromDecember 9-12, 2023. Treadwell also conducted a clinical advisory board meeting on December)] TJ ET BT 35.000 604.915 Td /F1 12.0 Tf [(10th at ASH with experienced experts in the treatment of AML and in clinical trials of novel agents,)] TJ ET BT 35.000 590.263 Td /F1 12.0 Tf [(which included current investigators and thought leaders new to the program.)] TJ ET BT 35.000 563.611 Td /F1 12.0 Tf [(??CFI-400945 is demonstrating complete remissions as a single agent and in combination with)] TJ ET BT 35.000 548.959 Td /F1 12.0 Tf [(azacitadine in relapsed, adverse risk AML, including those with )] TJ ET BT 371.804 548.959 Td /F4 12.0 Tf [(TP53)] TJ ET BT 400.484 548.959 Td /F1 12.0 Tf [( mutant disease. As we optimize)] TJ ET BT 35.000 534.307 Td /F1 12.0 Tf [(dose and schedule, we are encouraged by the data with this oral dosing regimen,?)] TJ ET BT 479.900 534.307 Td /F1 12.0 Tf [()] TJ ET BT 483.236 534.307 Td /F1 12.0 Tf [(said Principal)] TJ ET BT 35.000 519.655 Td /F1 12.0 Tf [(Investigator and Advisory Board Co-Chair Dr.Gautam Borthakur, MD, Professor, Department of)] TJ ET BT 35.000 505.003 Td /F1 12.0 Tf [(Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. ??The)] TJ ET BT 35.000 490.351 Td /F1 12.0 Tf [(advisory board confirmed the enthusiasm about the data to date in the relapsed AML setting, in)] TJ ET BT 35.000 475.699 Td /F1 12.0 Tf [(particular with )] TJ ET BT 112.352 475.699 Td /F4 12.0 Tf [(TP53)] TJ ET BT 141.032 475.699 Td /F1 12.0 Tf [( mutant disease and look forward to working with Treadwell to advance and shape)] TJ ET BT 35.000 461.047 Td /F1 12.0 Tf [(this program.?)] TJ ET BT 118.364 461.047 Td /F1 12.0 Tf [()] TJ ET BT 35.000 434.395 Td /F1 12.0 Tf [(??CFI-400945, our lead program and first-in-class PLK4 inhibitor, represents an opportunity to)] TJ ET BT 35.000 419.743 Td /F1 12.0 Tf [(address a substantial unmet in relapsed/refractory AML, including )] TJ ET BT 386.480 419.743 Td /F4 12.0 Tf [(TP53)] TJ ET BT 415.160 419.743 Td /F1 12.0 Tf [( mutant AML,?)] TJ ET BT 499.868 419.743 Td /F1 12.0 Tf [()] TJ ET BT 503.204 419.743 Td /F1 12.0 Tf [( said Roger)] TJ ET BT 35.000 405.091 Td /F1 12.0 Tf [(Sidhu, MD, Acting CEO at Treadwell Therapeutics. ??We look forward to advancing the program into)] TJ ET BT 35.000 390.439 Td /F1 12.0 Tf [(key dose expansion studies in monotherapy and in combination in 2024 with a view to initiating pivotal)] TJ ET BT 35.000 375.787 Td /F1 12.0 Tf [(studies in 2025.?)] TJ ET BT 132.392 375.787 Td /F1 12.0 Tf [()] TJ ET BT 35.000 349.135 Td /F3 12.0 Tf [(2023 ASH Poster Presentations and Details:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 346.525 m 285.080 346.525 l S BT 35.000 322.483 Td /F3 12.0 Tf [(Title)] TJ ET BT 59.672 322.483 Td /F1 12.0 Tf [(: Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study)] TJ ET BT 35.000 307.831 Td /F1 12.0 Tf [(of the Safety, Tolerability, and Pharmacokinetic \(PK\) and Pharmacodynamic \(PD\) Profiles of CFI-)] TJ ET BT 35.000 293.179 Td /F1 12.0 Tf [(400945 As a Single Agent or in Combination with Azacitidine in Patients \(Pts\) with Acute Myeloid)] TJ ET BT 35.000 278.527 Td /F1 12.0 Tf [(Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia \(TWT-202\))] TJ ET BT 35.000 263.875 Td /F3 12.0 Tf [(Session Name)] TJ ET BT 117.032 263.875 Td /F1 12.0 Tf [(: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation)] TJ ET BT 35.000 249.223 Td /F1 12.0 Tf [(and Cellular Immunotherapies:PosterIII)] TJ ET BT 35.000 234.571 Td /F3 12.0 Tf [(Publication Number)] TJ ET BT 148.352 234.571 Td /F1 12.0 Tf [(: 4294)] TJ ET BT 35.000 219.919 Td /F3 12.0 Tf [(Session Date)] TJ ET BT 110.360 219.919 Td /F1 12.0 Tf [(: Monday, December 11, 2023)] TJ ET BT 35.000 205.267 Td /F3 12.0 Tf [(Presentation Time)] TJ ET BT 139.028 205.267 Td /F1 12.0 Tf [(: 6:00 PM ?? 8:00 PM)] TJ ET BT 35.000 190.615 Td /F3 12.0 Tf [(Location)] TJ ET BT 85.004 190.615 Td /F1 12.0 Tf [(: San Diego Convention Center, Halls G-H)] TJ ET BT 35.000 163.963 Td /F1 12.0 Tf [(CFI-400945 has been generally well tolerated in this difficult to treat patient population, including)] TJ ET BT 35.000 149.311 Td /F1 12.0 Tf [(patientswhose disease has progressed on or following venetoclax based therapies??.)] TJ ET BT 35.000 122.659 Td /F1 12.0 Tf [(Three of 6 evaluable patients with AML achieved a response \(MLFS=2,CRi=1 with MRD+\) at the)] TJ ET BT 35.000 108.007 Td /F1 12.0 Tf [(96mgdose??. After thisdata cut,one additional MLFS response \(end of cycle 1\) and two)] TJ ET BT 35.000 93.355 Td /F1 12.0 Tf [(additionalCRs\(end ofcycle 2\) were seen in two patients treated with 80 mg + azacitidine combination)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Font /Subtype /Type1 /Name /F4 /BaseFont /Helvetica-Oblique /Encoding /WinAnsiEncoding >> endobj 12 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 14 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 16 0 R 18 0 R ] /Contents 15 0 R >> endobj 15 0 obj << /Length 2213 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(cohort and became transplant eligible \()] TJ ET BT 241.760 820.168 Td /F4 12.0 Tf [(PIcommunication)] TJ ET BT 337.124 820.168 Td /F1 12.0 Tf [(\)??. PK characteristics support daily dosing)] TJ ET BT 35.000 805.516 Td /F1 12.0 Tf [(of CFI-400945 and PD studies are ongoing??. Dose expansions are planned and enrollment)] TJ ET BT 35.000 790.864 Td /F1 12.0 Tf [(continues??.)] TJ ET BT 35.000 760.180 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 730.990 Td /F1 12.0 Tf [(Treadwell Therapeutics is a clinical-stage oncology company developing novel medicines to address)] TJ ET BT 35.000 716.338 Td /F1 12.0 Tf [(unmet needs in patients with cancer. The Company??s robust, internally developed clinical pipeline)] TJ ET BT 35.000 701.686 Td /F1 12.0 Tf [(includes CFI-400945 \(PLK4 inhibitor\), CFI-402257 \(TTK/Mps1 inhibitor\) and CFI-402411 \(HPK1)] TJ ET BT 35.000 687.034 Td /F1 12.0 Tf [(inhibitor\). Treadwell also has a broad pre-clinical pipeline with multiple biologic and next generation)] TJ ET BT 35.000 672.382 Td /F1 12.0 Tf [(TCR based autologous cell therapy programs. For more information, please visit )] TJ ET 0.000 0.000 0.800 rg BT 463.820 672.382 Td /F1 12.0 Tf [(www.treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 463.820 669.772 m 576.500 669.772 l S 0.000 0.000 0.000 rg BT 576.500 672.382 Td /F1 12.0 Tf [(.)] TJ ET BT 35.000 641.697 Td /F3 14.0 Tf [(Contact)] TJ ET 0.000 0.000 0.800 rg BT 35.000 612.507 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 35.000 609.897 m 137.192 609.897 l S 0.000 0.000 0.000 rg BT 35.000 585.855 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 571.203 Td /F1 12.0 Tf [(December 18, 2023)] TJ ET q 35.000 568.272 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 16 0 obj << /Type /Annot /Subtype /Link /F 28 /A 17 0 R /Border [0 0 0] /H /I /Rect [ 463.8200 670.0506 576.5000 682.2606 ] >> endobj 17 0 obj << /Type /Action /S /URI /URI (https://treadwelltx.com/) >> endobj 18 0 obj << /Type /Annot /Subtype /Link /F 28 /A 19 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 610.1757 137.1920 622.3857 ] >> endobj 19 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj xref 0 20 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000355 00000 n 0000000384 00000 n 0000000533 00000 n 0000000636 00000 n 0000006928 00000 n 0000007035 00000 n 0000007144 00000 n 0000007257 00000 n 0000007373 00000 n 0000007430 00000 n 0000007487 00000 n 0000007618 00000 n 0000009884 00000 n 0000010018 00000 n 0000010094 00000 n 0000010227 00000 n trailer << /Size 20 /Root 1 0 R /Info 5 0 R /ID[<988cf2a12fcedf2323f1d4124cb4f0c7><988cf2a12fcedf2323f1d4124cb4f0c7>] >> startxref 10304 %%EOF